Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank-check company formed to identify and complete a business combination within the biomedical and life sciences sector. The company completed its initial public offering in 2021 and filed a Form 10-Q with the SEC on May 23, 2022, reporting on its quarterly operations while continuing its search for a merger target. As of that filing, EUCR remained in the pre-combination phase, with its management team actively evaluating acquisition candidates across the broader healthcare and biomedical landscape. Visit SpacDesk and sign up for full access to EUCR's filing history, deal timelines, and comparable SPAC data.